Protagenic Therapeutics, Inc.\new Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Protagenic Therapeutics, Inc.\new (PTIX) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $0.56 per share as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2026-08-19
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $0.56.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $4.84.
- 2022-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $1.21.
- 2022-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $1.21.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price |
|---|---|
| 2026-06-30 | $0.56 10-Q · filed 2026-08-19 |
| 2022-12-31 | $4.84 10-K/A · filed 2024-05-14 |
| 2022-09-30 | $1.21 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.21 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.21 10-Q · filed 2022-05-13 |
| 2021-03-31 | $5.60 10-Q · filed 2021-05-17 |
| 2020-12-31 | $1.75 10-K · filed 2022-04-07 |
| 2020-09-30 | $1.75 10-Q · filed 2020-11-16 |
| 2020-06-30 | $1.75 10-Q · filed 2020-08-14 |
| 2020-03-31 | $1.75 10-Q · filed 2020-06-18 |
| 2019-03-31 | $1.00 10-Q · filed 2019-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |